. Author manuscript; available in PMC: 2020 Dec 5.

Published in final edited form as: Lancet HIV. 2019 Dec 6:S2352-3018(19)30337-6. doi: 10.1016/S2352-3018(19)30337-6

Table 3:

Virologic failure (≥400 copies/µL) by nevirapine- versus efavirenz-based antiretroviral therapy and pretreatment drug resistance

Pretreatment drug resistance: categorization and mutant frequency	Nevirapine		Efavirenz
	N	n (%) VF	N	n (%) VF	p-value
Total	273	39 (14%)	497	29 (6%)	<0·01

Wild-type; <2%	258	30 (12%)	472	22 (5%)	<0·01

Pretreatment drug resistance	15	9 (60%)	25	7 (28%)	0·05

Low frequency resistance; 2–9%^*	3	2 (67%)	6	1 (17%)	0·23

Resistant; ≥10%	12	7 (58%)	19	6 (32%)	0·14

Abbreviations: VF, virologic failure;

Fisher’s exact test